Sam S. Chang, MD, MBA

Sam S. Chang, MD, MBA

Vanderbilt University School of Medicine

Nashville, TN

Focusing on urologic oncology and education, Dr. Chang has led efforts in integration of evidence-based medicine in clinical pathways, enhanced guidelines formulation and improved cancer staging. He has orchestrated the initiation and expansion of multiple cancer-related treatment protocols at Vanderbilt and elsewhere. As Chairman of the SUO Panel on Hormone Refractory Prostate Cancer and the Vice Chair of the AUA Guidelines on Noninvasive Bladder Cancer, Dr. Chang successfully combined expert opinion with study results. As an AUA-EAU Academic Exchange Fellow, he further promoted critical evidentiary analysis and educational reforms. He currently serves as the Facilitator on the Renal Malignancy Follow-Up AUA Guidelines Panel and chairs the AUA Prostate Cancer Core Curriculum Committee. Dr. Chang is currently the chair of the American Joint Committee on Cancer (AJCC) GU Staging Task force and a member of the U.S. Committee on Cancer. Earlier, his research verified PSMA antigenic expression in tumor neo-vasculature of multiple tumors. This work serves as the basis for ongoing research on targeted antibody diagnostic and therapeutic applications. Dr. Chang has authored more than 200 original publications. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, the CaPCURE Young Investigator Award, and was named a Journal of Urology’s Best Reviewer. Dr. Chang was named as the 2011 recipient of the prestigious American Urological Association Gold Cystoscope Award. Dr. Chang received his MD and his MBA from Vanderbilt University, Nashville, Tennessee.

Articles by Sam S. Chang, MD, MBA

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guidelines

Sam Chang, MD, MBA, who has served as chair of the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), provides an overview of updated non-metastatic MIBC treatment guidelines, including a comprehensive treatment algorithm. He also discusses directions of future research for the disease.

Read More

Robotic Cystectomy Versus Open Cystectomy: What Do We Know?

Sam Chang, MD, MBA, delineates the benefits and shortcomings of both robotic and open cystectomy, specifically in terms of morbidity, compilation, and recurrence rates for patients, and the learning curve associated with each method for clinicians. He also discusses how the financial cost of robotic surgery factors into this comparison.

Read More

Join the GRU Community

- Why Join? -